The company completed a $58.88 million private placement in October 2025 and deployed approximately $50 million to acquire Zcash (ZEC) as part of a new digital asset treasury strategy alongside its oncology pipeline. Leap showcases a strong clinical outlook with sirexatamab demonstrating a notable 39% objective response rate in patients with elevated DKK1 levels, positioning the company to engage with the FDA for potential regulatory pathway advancement.
Cyborg Score Rationale
Phase 2 sirexatamab data shows promising efficacy in DKK1-high colorectal cancer patients (ORR 38% vs 23.7% control, mPFS 9.03 vs 7.06 months), but the company faces significant execution risks. As of February 2026, market capitalization is only $24.8 million, indicating micro-cap volatility and limited financial runway despite recent fundraising.
Top Insights
DKN-01 demonstrates 38% response rate in DKK1-high colorectal cancer populations versus 23.7% in controls, with potential for FDA regulatory engagement
FL-501 (GDF-15 targeting antibody) planned for clinical trial entry in 2026 to address cancer cachexia, a condition lacking effective treatments
Recent corporate pivot to digital asset treasury strategy with Zcash acquisition signals diversified value strategy beyond pure oncology development
Micro-cap valuation ($24.8M) with 52-week price range of $0.22-$3.70 reflects extreme volatility typical of pre-commercialization biotech
Named Competitors
Claudin18.2-targeted therapeutics — Competing gastric/pancreatic cancer antibody programs
DKK1-pathway inhibition — Large pharma exploring similar Wnt pathway targets
Immuno-oncology monoclonal antibodies — Established competitors in cancer immunotherapy space
Recent Developments
(November 2025) Rebranded to Cypherpunk Technologies; completed $58.88M private placement; acquired $50M in Zcash (ZEC)
(October 2025) Private placement led by Winklevoss Capital to fund operations and digital asset treasury strategy
(September 2025) Presented Phase 2 DeFianCe study results showing sirexatamab benefit in DKK1-high colorectal cancer patients at ESMO 2025
Open the full interactive Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.